Drug Profile


Alternative Names: MG-0103; MGCD 0103; MGCD103; Mocetinostat dihydrobromide

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MethylGene
  • Developer MedImmune; MethylGene; Mirati Therapeutics
  • Class Antineoplastics; Benzamides; Pyrimidines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes; Diffuse large B cell lymphoma; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase Unknown Head and neck cancer
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Acute myeloid leukaemia; Hodgkin's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Monotherapy) in USA (PO)
  • 04 Aug 2017 Mirati Therapeutics initiates enrolment in a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease; Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03220477)
  • 25 Jul 2017 Memorial Sloan Kettering Cancer Center in collaboration with Merck, Astex Pharmaceuticals and Mirati Therapeutics plans a phase I trial of mocetinostat in combination with guadecitabine and pembrolizumab for Non small cell lung cancer (Late stage disease, Second line therapy, Combination therapy, Metastatic disease) in USA, in July 2017 (NCT03220477)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top